Answers are grounded in this paper and cite their sources.
A retrospective observational study shows ambrisentan improves exercise capacity more than sildenafil in congenital heart disease with pulmonary hypertension, indicating clinical benefit.
Background: The pathogenesis of PAH involves endothelial dysfunction characterised by over-expression of vasoconstrictors such as endothelin-1 (ET-1) and thromboxane A2. Endothelin receptor antagonists (ERAs) are a class of potent vasodilators and antimitotic substances. Aims&Objectives To assess the efficacy of endothelin receptor antagonists (ERAs) Ambrisentanin the treatment of patients with PAH secondary to congenital heart disease. Methods: It is a retrospective observational study, carried out at single tertiary care center. Patient of acyanotic congenital heart diseases (e.g.VSD, PDA, AV canal defect) admitted in cardiology department, found to have irreversible pulmonary hypertension on cardiac catheterization were enrolled in study. A total of 42 patients were enrolled in the study, 24 patients had received 10 mg of ambrisentan and remaining group 20 patient had received sildenafil at maximum tolerated dose for at least 6 months. Primary outcomes were exercise capacity (a six-minute walk test (6MWD)) and World Health Organization (WHO) functional class or New York Heart Association (NYHA) functional class. Secondary outcomeAdverse events (for example, hepatic toxicity). Results: An increase in the 6MWD was reported in the ambrisentan group . Increases in the 6MWDat 24weekswas 51meters in Ambrisentan group compared to 20 meters in sildenafil group.(95% CI 27e76; P , 0.001). Patient enrolled in the study were prominently WHO functional classification II (29%) and III (65%). Study demonstrated a significant improvement in WHO functional classification for patients receiving ambrisentan as compared with sildenafil (P 1⁄4 0.036). Of the patients receiving ambrisentan, 2 (9.7%) discontinued because of adverse events ( gastroenteritis,headache/face edema [n1⁄41 for each].Side effect of ambrisentanwas found to be headache 2 (9.0%), peripheral edema 4(18.18%).No evidence of hepatotoxicity like elevated liver enzymes, bilirubin in ambrisentan group. Conclusion: Study demonstrate the efficacy and safety of ambrisentan in the treatment of patients with symptomatic PAH. The favorable efficacy-to-safety profile of ambrisentan may offer potential advantages over the currently approved treatment options.
No takes yet. Share an insight, caveat, or question.
Raut et al. (2014) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: